In the battle of the obesity bulge, glucagon-like peptide-1 receptor agonist medications — aka GLP-1s such as Wegovy and Zepbound — have changed the game for some people who've struggled to ...

PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect ...

Add Yahoo as a preferred source to see more of our stories on Google. This image from video provided by UPMC and University of Pittsburgh Health Sciences shows Doug McCullough, who has spinal muscular ...

Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle ...

WILMINGTON, Del., Oct. 30, 2023 /PRNewswire/ -- The muscle wasting disorders market generated revenues worth US$ 12.7 billion in 2022. The market is predicted to reach US$ 45.4 billion in 2031.

Muscle loss, or atrophy, due to inactivity is common after illness, injury, hospitalization or falls, and becomes increasingly frequent with aging. New research published in Advanced Science shows ...